The broad partnership to discover and commercialize drugs in vascular biology, inflammatory diseases, and oncology announced this month between GlaxoSmithKline PLC and Exelixis Inc. [See Deal] recalls the halcyon big-deal era of 2000—when in a similarly structured transaction Novartis AG and Vertex Pharmaceuticals Inc. hooked up in a kinase target compound deal potentially worth $800 million [See Deal].
But the new deal's objects, structure, and value confirm industry changes in the last two-plus years. First, like Novartis/Vertex, GSK...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?